Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07063056 · ClinicalTrials.gov registry record · NA
Curcumin & Astaxanthin for Lowering Triglyceride Readings and Inflammation
A NA study of Triglycerides, sponsored by Medinutra.
- Recruiting
- Registry status
- NA
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT07063056: Recruiting NA study of Triglycerides, sponsored by Medinutra.
NCT07063056 is a NA study of Triglycerides that is actively recruiting participants, run by Medinutra. The registered enrollment target is 64 participants, roughly in line with the 70-participant average among 4 other Triglycerides trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07063056, a NA study of Triglycerides, is actively recruiting participants, sponsored by Medinutra.
- RECRUITING
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
Two dietary supplements are each being compared to a placebo for the ability to help maintain triglycerides in the normal range. The subjects will be adult men and women with moderately high TG values. Serum triglycerides will be measured before and after 6 weeks of taking 1 capsule per day of either Longvida Curcumin, astaxanthin, or a placebo. A few side blood analysis will also be done. These measures are relevant to low level inflammation.
Primary Outcome
Serum triglyceride readings (mg/dL)
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Astaxanthin
- OTHER Placebo Control
- DIETARY_SUPPLEMENT Curcumin (Longvida™)
- DIETARY_SUPPLEMENT Half Dose Curcumin (Longvida™)
Study Locations (1)
Ohio
- Medinutra LLC - Dublin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2025-12 |
| Phase | NA |
What NCT07063056 shows while recruiting
NCT07063056 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, roughly in line with the 70-participant average among 4 other Triglycerides trials with a reported enrollment target.
The record links to 1 condition, with Triglycerides appearing as the primary indexed condition, and to 4 interventions - of which Astaxanthin is the first listed.
NCT07063056 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07063056 about?
NCT07063056 is a clinical study titled "Curcumin & Astaxanthin for Lowering Triglyceride Readings and Inflammation". Two dietary supplements are each being compared to a placebo for the ability to help maintain triglycerides in the normal range. The subjects will be adult men and women with moderately high TG values. Serum triglycerides will be measured before and after 6 weeks of taking 1 capsule per day of eithe...
What is the current status of trial NCT07063056?
This trial is currently recruiting. It is a NA study. The enrollment target is 64 participants. The study started on 2025-07-18. Estimated completion is 2025-12.
What conditions does trial NCT07063056 study?
This clinical trial studies the following conditions: Triglycerides.
What interventions are being tested in trial NCT07063056?
The interventions under investigation include: Astaxanthin (DIETARY_SUPPLEMENT), Placebo Control (OTHER), Curcumin (Longvida™) (DIETARY_SUPPLEMENT), Half Dose Curcumin (Longvida™) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07063056?
This trial is sponsored by Medinutra, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07063056 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triglycerides
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
RECRUITING · NA
-
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
COMPLETED · Phase 2
-
Effect of Diet on Vascular Disease in Pre-Menopausal Women
COMPLETED
-
Identifying Risk for Diabetes and Heart Disease in Women
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI